The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Distinct Polymer Architecture Mediates Switching of Complement Activation Pathways at the Nanosphere−Serum Interface: Implications for Stealth Nanoparticle Engineering
Open accessAbstract
Nanoparticles with surface projected polyethyleneoxide (PEO) chains in "mushroom-brush" and "brush" configurations display stealth properties in systemic circulation and have numerous applications in site-specific targeting for controlled drug delivery and release as well as diagnostic imaging. We report on the "structure-activity" relationship pertaining to surface-immobilized PEO of various configurations on model nanoparticles, and the initiation of complement cascade, which is the most ancient component of innate human immunity, and its activation may induce clinically significant adverse reactions in some individuals. Conformational states of surface-projected PEO chains, arising from the block copolymer poloxamine 908 adsorption, on polystyrene nanoparticles trigger complement activation differently. Alteration of copolymer architecture on nanospheres from mushroom to brush configuration not only switches complement activation from C1q-dependent classical to lectin pathway but also reduces the level of generated complement activation products C4d, Bb, C5a, and SC5b-9. Also, changes in adsorbed polymer configuration trigger alternative pathway activation differently and through different initiators. Notably, the role for properdin-mediated activation of alternative pathway was only restricted to particles displaying PEO chains in a transition mushroom-brush configuration. Since nanoparticle-mediated complement activation is of clinical concern, our findings provide a rational basis for improved surface engineering and design of immunologically safer stealth and targetable nanosystems with polymers for use in clinical medicine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Long-Circulating and Target-Specific Nanoparticles: Theory to Practice
Moghimi, S. M., Hunter, A. C., & Murray, J. C. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01494-7 · Cited by 3,515
Self-citationNanomedicine: current status and future prospects
Moghimi, S. M., Hunter, A. C., & Murray, J. C. (2005) · The FASEB Journal · doi:10.1096/fj.04-2747rev · Cited by 2,029
Self-citationMoghimi, S. M., & Szebeni, J. (2003) · Progress in Lipid Research · doi:10.1016/s0163-7827(03)00033-x · Cited by 1,227
Self-citationSurface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system
Storm, G., Belliot, S. O., Daemen, T., & Lasic, D. D. (1995) · Advanced Drug Delivery Reviews · doi:10.1016/0169-409x(95)00039-a · Cited by 877
Evolution of the lectin–complement pathway and its role in innate immunity
Fujita, T. (2002) · Nature Reviews Immunology · doi:10.1038/nri800 · Cited by 697
Complement and coagulation: strangers or partners in crime?
Markiewski, M. M., Nilsson, B., Nilsson Ekdahl, K., Mollnes, T. E., & Lambris, J. D. (2007) · Trends in Immunology · doi:10.1016/j.it.2007.02.006 · Cited by 645
Complement activation-related pseudoallergy: A new class of drug-induced acute immune toxicity
Szebeni, J. (2005) · Toxicology · doi:10.1016/j.tox.2005.07.023 · Cited by 611
Complement-targeted therapeutics
Ricklin, D., & Lambris, J. D. (2007) · Nature Biotechnology · doi:10.1038/nbt1342 · Cited by 481
Chanan-Khan, A., Szebeni, J., Savay, S., Liebes, L., Rafique, N. M., Alving, C. R., & Muggia, F. M. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg374 · Cited by 479
Uziely, B., Jeffers, S., Isacson, R., Kutsch, K., Wei-Tsao, D., Yehoshua, Z., Libson, E., Muggia, F. M., & Gabizon, A. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.7.1777 · Cited by 477
Cited by
Biomolecular coronas provide the biological identity of nanosized materials
Monopoli, M. P., Åberg, C., Salvati, A., & Dawson, K. A. (2012) · Nature Nanotechnology · doi:10.1038/nnano.2012.207 · Cited by 3,017
Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology
Tenzer, S., Docter, D., Kuharev, J., Musyanovych, A., Fetz, V., Hecht, R., Schlenk, F., Fischer, D., Kiouptsi, K., Reinhardt, C., et al. (2013) · Nature Nanotechnology · doi:10.1038/nnano.2013.181 · Cited by 2,283
Salvati, A., Pitek, A. S., Monopoli, M. P., Prapainop, K., Bombelli, F. B., Hristov, D. R., Kelly, P. M., Åberg, C., Mahon, E., & Dawson, K. A. (2013) · Nature Nanotechnology · doi:10.1038/nnano.2012.237 · Cited by 1,912
Targeted polymeric therapeutic nanoparticles: design, development and clinical translation
Kamaly, N., Xiao, Z., Valencia, P. M., Radovic-Moreno, A. F., & Farokhzad, O. C. (2012) · Chemical Society Reviews · doi:10.1039/c2cs15344k · Cited by 1,730
Treating metastatic cancer with nanotechnology
Schroeder, A., Heller, D. A., Winslow, M. M., Dahlman, J. E., Pratt, G. W., Langer, R., Jacks, T., & Anderson, D. G. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3180 · Cited by 1,159
Mechanisms and biomaterials in pH-responsive tumour targeted drug delivery: A review
Kanamala, M., Wilson, W. R., Yang, M., Palmer, B. D., & Wu, Z. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.01.061 · Cited by 1,004
Pelaz, B., del Pino, P., Maffre, P., Hartmann, R., Gallego, M., Rivera-Fernández, S., de la Fuente, J. M., Nienhaus, G. U., & Parak, W. J. (2015) · ACS Nano · doi:10.1021/acsnano.5b01326 · Cited by 890
The journey of a drug-carrier in the body: An anatomo-physiological perspective
Bertrand, N., & Leroux, J.-C. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.098 · Cited by 707
Complement proteins bind to nanoparticle protein corona and undergo dynamic exchange in vivo
Chen, F., Wang, G., Griffin, J. I., Brenneman, B., Banda, N. K., Holers, V. M., Backos, D. S., Wu, L., Moghimi, S. M., & Simberg, D. (2017) · Nature Nanotechnology · doi:10.1038/nnano.2016.269 · Cited by 599
Self-citationEmerging concepts in dendrimer‐based nanomedicine: from design principles to clinical applications
Kannan, R. M., Nance, E., Kannan, S., & Tomalia, D. A. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12280 · Cited by 542
Safety of Nanoparticles in Medicine
Wolfram, J., Zhu, M., Yang, Y., Shen, J., Gentile, E., Paolino, D., Fresta, M., Nie, G., Chen, C., Shen, H., et al. (2015) · Current Drug Targets · doi:10.2174/1389450115666140804124808 · Cited by 532
Biodegradable Polymer Nanogels for Drug/Nucleic Acid Delivery
Li, Y., Maciel, D., Rodrigues, J., Shi, X., & Tomás, H. (2015) · Chemical Reviews · doi:10.1021/cr500131f · Cited by 478
Szebeni, J. (2014) · Molecular Immunology · doi:10.1016/j.molimm.2014.06.038 · Cited by 457
Designing the nanoparticle–biomolecule interface for “targeting and therapeutic delivery”
Mahon, E., Salvati, A., Baldelli Bombelli, F., Lynch, I., & Dawson, K. A. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.04.009 · Cited by 385
Questioning the use of PEGylation for drug delivery
Verhoef, J. J. F., & Anchordoquy, T. J. (2013) · Drug Delivery and Translational Research · doi:10.1007/s13346-013-0176-5 · Cited by 342
Stealth Properties to Improve Therapeutic Efficacy of Drug Nanocarriers
Salmaso, S., & Caliceti, P. (2013) · Journal of Drug Delivery · doi:10.1155/2013/374252 · Cited by 340
Nanoparticles and innate immunity: new perspectives on host defence
Boraschi, D., Italiani, P., Palomba, R., Decuzzi, P., Duschl, A., Fadeel, B., & Moghimi, S. M. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.08.013 · Cited by 310
Self-citationNanoparticles for Imaging, Sensing, and Therapeutic Intervention
Bogart, L. K., Pourroy, G., Murphy, C. J., Puntes, V., Pellegrino, T., Rosenblum, D., Peer, D., & Lévy, R. (2014) · ACS Nano · doi:10.1021/nn500962q · Cited by 295
Nanotechnologies for Alzheimer's disease: diagnosis, therapy, and safety issues
Brambilla, D., Le Droumaguet, B., Nicolas, J., Hashemi, S. H., Wu, L.-P., Moghimi, S. M., Couvreur, P., & Andrieux, K. (2011) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2011.03.008 · Cited by 294
Self-citationMaterial properties in complement activation
Moghimi, S. M., Andersen, A. J., Ahmadvand, D., Wibroe, P. P., Andresen, T. L., & Hunter, A. C. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.06.002 · Cited by 268
Self-citationFormation of the Protein Corona: The Interface between Nanoparticles and the Immune System
Barbero, F., Russo, L., Vitali, M., Piella, J., Salvo, I., Borrajo, M. L., Busquets-Fité, M., Grandori, R., Bastús, N. G., Casals, E., et al. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.10.001 · Cited by 263
Control of innate immune response by biomaterial surface topography, energy, and stiffness
Abaricia, J. O., Farzad, N., Heath, T. J., Simmons, J., Morandini, L., & Olivares-Navarrete, R. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.04.021 · Cited by 199
Padín-González, E., Lancaster, P., Bottini, M., Gasco, P., Tran, L., Fadeel, B., Wilkins, T., & Monopoli, M. P. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.882363 · Cited by 166
The impact of protein corona on the biological behavior of targeting nanomedicines
Farshbaf, M., Valizadeh, H., Panahi, Y., Fatahi, Y., Chen, M., Zarebkohan, A., & Gao, H. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.121458 · Cited by 95
Engineering biomaterials surfaces to modulate the host response
Yu, K., Mei, Y., Hadjesfandiari, N., & Kizhakkedathu, J. N. (2014) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2014.08.009 · Cited by 58
Metadata
- Authors
- Hamad, I., Al-Hanbali, O., Hunter, A. C., Rutt, K. J., Andresen, T. L., & Moghimi, S. M.
- Venue
- ACS Nano
- Publisher
- American Chemical Society (ACS)
- Published
- 2010-10-28
- Volume
- 4
- Issue
- 11
- Pages
- 6629-6638
- ISSN
- 1936-0851 (ISSN-L)
- 1936-086X
- OpenAlex
- W2102606231
- Cited by
- 276
- References
- 39
- FWCI
- 9.48
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
